Back to top
Protocol Chair(s)
Beigi, Richard (Protocol Co-Chair)
Noguchi, Lisa (Protocol Chair)
MTN-029 is a Phase I study that seeks to determine whether a vaginal ring containing the antiretroviral (ARV) drug dapivirine is a safe method for protecting against HIV infection when used by lactating women by assessing whether and how dapivirine is expressed in breast milk.
Protocol Chair(s)
Cranston, Ross (Protocol Chair)
MTN-026 is a Phase I study that seeks to evaluate the safety and systemic and local pharmacokinetics (PK) of a rectal gel containing the antiretroviral (ARV) drug dapivirine. The study will enroll approximately 24 men and women at two U.S. sites and take approximately 9-12 months to conduct.